东曜药业-B：截至2024年12月31日止年度全年业绩公告

TOT BIOPHARM International Company Limited 1875 20241231 2024 •1,098,32941%877,41039%®CDMO/CMO207,13347%2024116,403 •CDMO202434,757 •CDMO58ADC481532pre-BLA8CDMO1.9139% •GMPGMP202438GMP7GMP342QP1GMPPMDAMNC 2024123120231231 20241231 202410 (ADC)ADCADCADCADCNMPACDMOCDMO CDMO4 ADCBDKcellTMGMP12g/LCMCDisacLinkTMADCCDMOCDMOADCpre–BLA NMPAFDAGMPPMDACDMO 2025CDMOCDMO 2025311 36,956(36,020) 779,117739,415 1,508,7721,426,101 327,914310,689 1 200912433191918 CDMOCMO 2019118 2 2.1 2.1.1 622 2.1.2 2.1.3 2.1.4 (a) CDMO/CMO (b) 123120242023 CDMO/CMOCDMO (c) 202420231231 123120242023 123120242023 (a) 16.5%202316.5%202412312023 (b) 25%15%202325%15%20241231 202320252024123115%202315% (c) 20%202320%20241231 6 (a) (b) 202412312023202412310.0520230.05 7 2023 8 123120242023157,72885,9643,1836,977(1,169)(175)(2,464)(4,614)157,27888,152 123120242023 157,72885,964 202420231231 202412312023 9 (i) (i) 2024123120231231 3366121223 10 (i) (ii) 2024123147,590,9482023 20241,098,3292023780,629317,70041%202434,757202337,757202479,3132023103,890202481,375202368,3102024606,7112023441,019 CDMO/CMO 2024877,4102023630,207247,203® 2024CDMO/CMO207,1332023140,89866,235CDMO/CMO CDMO 202479,3132023103,89024,577ADC CDMO 2024606,7112023441,019165,692 202481,375202368,31013,065 20248,005202311,481 202418,216202317,654562 20243,38320232,974409 20249,88020235,1754,705 202420231 202434,757202337,757 20241231729,6552023686,68642,969 20241231381,2562023351,60029,656 2024116,403202356,43159,972CDMO122,5052023164,10541,60034,183202338,2254,042 20241231394,01320231231344,285299,05020231231265,715 202412310.5202312310.5 20211191.82021123183,50020211231202412318,35043,489 2021ADC2024123114,821 20241231 20241231 20241231 20241231 2024CDMO124CDMOCDMOCDMOCDMO CDMO 2024CDMOCDMOADCXDCADCGMPADCXDC ®2025 20241231 •1,098,32941% •877,41039%®CDMO/CMO207,13347%2024116,403•CDMO34,757•CDMO 58ADC 481532pre-BLA8CDMO1.9139% (ADC) 1. 2024ADCADC2000ADC17ADC2023ADC10ADCADC201820202310439.1%2023203030.3%2030ADC662 2.ADC CDMOADC ADCADCCDMOADCADC CDMOADC CDMOADCADCADCADC CDMO CDMO 1.CDMO ADCXDC 20241231 •CDMO/CMO207,13347%ADC86%•5848ADC•8pre-BLA2•MNC• 2.CDMO –2.1· ••ADCCDMO ADC –2.2GMP ICH Q10FDAALOCA+GMPGMP(NMPA)FDAGMPGMPGMP202438GMP7GMP342QP1GMPPMDACDMO (DMS)(ERP)(EMS)VAISALA(LIMS)(ELN)CDMOGMP ADC CDMO 20237GL-DisacLink™ ADCCDMOXDCGL-DisacLink® ADCCMC 2024OSHydroTrioOSADC/BioconjugatesOSADC HydroTrioDAR –2.4 422ADC54303,000ADC9605302023CDMOCDMOADCADC pre-BLACDMOADC CDMO –2.5CDMO 2024CDMO15+20241231CDMOCDMO75%ADC CDMO17%85%2024CDMO 2.6 CDMO2024ADCXDC 2024CDMO 20223TAB014(wAMD)TAB014(MAH)20251B (6622.HK)TAB014IIITAB014 ADC CDMO2024 18A.05 ® ®202120241231®Avastin®1002030490202120307.6%2030184202120308.3%®2022® 202442%2024123134202025 ® ®2021531NMPA2021®202220241231 GMPADCCDMO20,000LADC100L500L5kg6,000~50,000GMPADCADC 2024CDMOADC/XDC/AXCCDMOCDMO 2024 •20244XDCXDCAb/ADC/XDCCDMOADC •20246BiG&ADCADCCDMO •20246(CBA-China)ADC/XDCCDMOADCCBA-ChinaCBA-China •20249BioJapanBioJapan •202410ADCSAPA-China 2024ADC •202411ADC&XDCGL-DisacLink® •202411World ADC(ADCs)World ADCADC 2024CDMO CDMO 20241231 20241231 20241231 C1 20241231 C320241231 2022531150,000,0003.15 2022722 2022729(i)33,750,000(ii)116,250,000 472,500,000405,788471,116,000404,593 2022531202262220226302022729202275 20243152024202420243152023 202412312024 2024123172,1322024123138,224 2025311TAE020ADCTAC02010,000202520252025 2024123120252024 20241231 (www.totbiopharm.com.cn)(www.hkexnews.hk)20242025 20241231622436 662(3)6320241231 20241231406(2)407(2)(3) 2025311